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A B S T R A C T
In this study, we aimed to evaluate motor cortical excitability changes in patients with juvenile
myoclonic epilepsy (JME) and their asymptomatic siblings (AS) using single-pulse transcranial magnetic
stimulation (spTMS). 21 patients with JME and their 21 AS were compared to 20 healthy controls. All of
JME patients were receiving antiepileptic therapy and their seizures were well controlled. Firstly,
standard EEG examinations and then TMS studies were performed. Resting motor threshold (RMT),
motor evoked potential (MEP) amplitudes, the durations of central motor conduction time (CMCT) and
cortical silent period (CSP) were measured. After TMS studies, EEG recordings were repeated in an hour
to evaluate any effect of TMS study on EEG. There were no signiﬁcant differences between the ﬁrst and
second EEG recordings. No seizures were recorded during and after the TMS study. RMT was found
higher in JME patients than AS and normal controls. There were no signiﬁcant differences between
cortical MEP amplitudes andMEP amplitude/CMAP (compoundmuscle action potential) amplitude ratio
in all three groups. CMCT duration was shorter in JME patients than AS. CSP durations of JME patients
were found to be longer than controls. In AS, CSP durationswere also found to be longer than controls but
this difference was not found statistically signiﬁcant. Our results suggested that although high MT may
be related to antiepileptic therapy, the prolongation of CSP duration may reﬂect impairment of
supraspinal and/or intracortical inhibitory mechanism in JME. To eliminate the drug effect, further
studies are needed in newly diagnosed JME patients without medication and large series of their
asymptomatic siblings.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
journa l homepage: www.e lsev ier .com/ locate /yse iz1. Introduction
Transcranial magnetic stimulation (TMS) is a non-invasive and
painless technique which was introduced by Barker et al. in 1985.
It works by creating a very large transient current which passes
through the coil, produces a magnetic ﬁeld and induces electrical
current in other conductors (e.g. brain, spinal roots or nerves). TMS
can be applied for understanding the physiology and the
excitability of the motor cortex.1–5 It has been used in different
epileptic syndromes to investigate the localization of epileptic foci
or speech function, changes of the cortical excitability or effects of
the antiepileptic therapy (AT).1–3,5–25 Former studies have shown
that epileptogenesis is consisted of both excitatory and inhibitory
mechanisms and TMS can be used for evaluating both excitatory
and inhibitory effects on motor cortex.2,5,26–31* Corresponding author at: Atakoy ﬁfth, Kisim E1/1A Blok Daire: 8, 34158
Bakirkoy, Istanbul, Turkey.
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doi:10.1016/j.seizure.2009.02.002Motor threshold (MT) refers to the lowest stimulus intensity
needed to generate the response in the target muscle and
anatomically may reﬂect the density of network targeting the
corticomotor neurons and physiologically may indicate the level of
corticospinal system excitability.2,5,6,18,27,30,32,33 Besides exhibit-
ing a motor evoked potential, a period of EMG suppression known
as silent period (SP) occurs after single-pulse TMS during voluntary
contraction.2,5,6,27,32 Although the spinal and direct spinal inhibi-
torymechanisms are involved in the early and intermediate part of
SP, the late part of SP is thought to be related to intracortical
inhibitory mechanisms in primary motor cortex, leading to a
failure of corticospinal drive.2,3,5,6,27,32,34,35 It has been suggested
that using a single stimulus, (GABA)B-ergic intracortical circuits
contribute to the generation of transcranially evoked SP, however,
short interval intracortical inhibition (SICI) is mediated by
(GABA)A-ergic intracortical circuits using paired stimuli. This
opinion was supported by pharmacologic studies using GABA
agonists such as benzodiazepines, baclofen, tiagabin, vigabatrin,
zolpidem.5,17,19,23,27,32,36,37 Central motor conduction time (CMCT)
is an estimation of the conduction time in central motor pathways
from motor cortex to the spinal motor neurons.5,6 CMCT durationvier Ltd. All rights reserved.
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motor neurons conducted via the corticospinal/corticobulbar
tracts.5
Juvenile myoclonic epilepsy (JME) is one of the generalized
idiopathic epileptic syndromes with complex inheritance pat-
tern.38–40 It is characterized by irregular myoclonic jerks of the
shoulders and arms upon waking without any disturbance of
consciousness, typical absence or generalized tonic clonic sei-
zures.25,38–42 Typical EEG ﬁndings of JME are bilateral synchro-
nous, 4–6 Hz spike/multiple spike and slowwaves complexes.38–41
Different types of idiopathic epileptic syndromes were found in
relatives of JME patients.38–40 In some earlier reports, EEG
abnormalities were demonstrated in siblings of JME
patients.38,40,42 In our previous study, we found EEG and
somatosensory evoked potential (SEP) abnormalities not only in
JME patients but also in their asymptomatic siblings.40 In the
literature, some TMS studies in epileptic patients had controversial
results. Moreover, there were no TMS studies which were
performed in asymptomatic siblings of epileptic patients. In this
study, we mainly aimed to evaluate motor cortical excitability
changes in JME patients and their asymptomatic siblings using
single-pulse TMS (spTMS). The second aim of this study was to
assess the safety of spTMS in this population.
2. Materials and methods
2.1. Subjects
There were three groups in this study. The ﬁrst group consisted
of 21 patients with JME (10F, 11 M; mean age SD: 23.9  3.4;
range: 17–31) gathered from our epilepsy outpatient clinic. The
second group consisted of their 21 asymptomatic siblings (12F, 9 M;
mean age SD: 22.8  5.0; range: 13–33). They were all compared to
20 healthy controls (10F, 10 M;mean ageSD: 23.6  5.7; range: 13–
33).
JME diagnosis was established according to clinical history and
EEG ﬁndings. All of JME patients were receiving antiepileptic
therapy and their seizures were well controlled. Patients who had
generalized tonic clonic seizures in the last one year were
excluded. None of the controls or asymptomatic siblings was
taking any drugs which effect on central nervous system
excitability such as sedatives, hypnotics, anticonvulsants or
beta-blockers. All participants had normal neurological examina-
tion before and after the study. In all JME patients, CT and/or MR
imagings were normal. The duration of the disease was 120  47.6
months (mean  SD; range: 36–228 months). First seizure type was
myoclonic in 13 patients, generalized tonic clonic in 6 patients and
absence in 2 patients. All of the patients had myoclonic jerks, except
one patient (95.2%). Nine patients (42.9%) had absence, 17 patients
(81%) experienced at least one generalized tonic clonic seizure
throughout the disease duration. All of the patients were treated
chronically with antiepileptic drugs (AED): Nineteen (90.5%) with
valproic acid (VPA), one (4.8%) with VPA and lamotrigine (LTG) and
one (4.8%) with VPA, LTG and Phenobarbital (PB). VPA dosage varied
from 500 mg to 1500 mg, LTG dosage was 50 mg and PB dosage was
100 mg. The dosages of all antiepileptic drugs (AED) were within the
therapeutic range at the last clinical admission.
The study was reviewed and approved by a local ethical
committee. A written, informed consent form was collected from
all subjects who were participated in the study.
2.2. Experimental procedures and recordings
Initially, standard EEG recordings including hyperventilation
and photic stimulation were performed with a Medelec1118
device. In order to evaluate any effect of TMS study on EEG, asecond EEG recording in each participant was done within the ﬁrst
hour after TMS.
During TMS studies, subjects were sitting on a comfortable
armchair in a quiet, semi-darkened room. Hand dominancy was
conﬁrmed by the Edinburgh Handedness Test.43 Motor evoked
potential (MEP) responses were recorded from dominant hand
abductor digiti minimi (ADM)muscle with Ag/AgCl cup electrodes.
The active electrode was placed on the muscle belly and the
reference over the ﬁfth metacarpophalangeal joint. Initially, the
ulnar nerve was stimulated at the dominant wrist using electrical
stimulator and the amplitude of resulting compoundmuscle action
potential (CMAP) was measured. Single-pulse magnetic stimula-
tion was performed using a 135 mm circular coil connected to
Magstim200 stimulator over the vertex. If left hemisphere was
dominant, the direction of the current in the coil was anticlockwise
and if right hemisphere was dominant the direction of the current
in the coil was clockwise. MEP responses were recorded by
Medelec Sapphire 4ME device.
While the subjects were resting, motor threshold (RMT) was
determined. Audio-visual feedback was given to the subjects in
order to maintain complete electrical muscle silence. RMT was
deﬁned as the stimulus intensity at which a peak-to-peak MEP
amplitude of 50 mV was obtained in at least 5 of 10 consecutive
trials. During active muscle contraction, using 120% of the RMT as
stimulus intensity, the shortest onset latency and the highest
amplitude of 7 consecutive MEPs were obtained and latency and
amplitude were measured. In order to avoid possible variability of
MEP amplitudes, MEP amplitude/CMAP amplitude ratio (MEP/
CMAP) was calculated. Cervical roots were stimulated over the
spinous process of the 7th cervical vertebra at maximal stimulator
output when the subject was in a sitting position with a slight
degree of neck ﬂexion. Central motor conduction time (CMCT) was
calculated by subtracting the latency of cervical response from the
latency of cortical MEP response.
During CSP studies, subjects were held slight contraction of
approximately 30% maximum voluntary contraction of contral-
ateral ADM muscle. Audio-visual feedback was given to maintain
the correct level activity. Stimulus intensitywasmaximal output of
magnetic stimulator. 5 consecutive stimuli were delivered. The
duration of CSP was measured from the end of the MEP until the
reappearance of EMG activity and the shortest CSP value was
selected for evaluation.
2.3. Statistics
Statistical analysis was performed using SPSS for Windows
program. Sex and EEG results were compared to Chi-square test.
Kappa test was used for comparing EEG results before and after
TMS. TheMEP results of three groups were compared to analysis of
variance (ANOVA) tests with post hoc Bonferroni and Dunnet tests.
A p value of <0.05 was considered to be statistically signiﬁcant.
3. Results
The demographic data and clinical characteristics of the study
are described in Table 1. There were no signiﬁcant differences
between sex and the mean age of study groups (p = 0.814;
F = 0.292, p = 0.748 respectively).
Before TMS examinations, six JME patients and one asympto-
matic sibling had 4–6 Hz spike/polyspike and wave paroxysms
(SPSWP). Three JME patients and 6 asymptomatic siblings had 6–
7 Hz theta activity mixed with normal activity. This activity was
deﬁned as intermittent generalized slowing (IGS). After TMS
examinations, we found 4–6 Hz spike/polyspike and wave
paroxysms in 5 JME patients and one asymptomatic sibling; and
we found IGS in 3 JME patients and 6 asymptomatic siblings
Table 1
Demographic data and clinical characteristics of the study.
JME AS CONTROLS p
Mean of age (range) 23.9  3.4 (17–31) 22.8  5.0 (13–33) 23.6  5.7 (13–33) 0.748
Sex 11M/10F 9M/12F 10M/10F 0.814
Duration of disease (months) 120  47.6 (36–228)
First seizure type
Myoclonic 13
GTCS 6
Absence 2
Therapy
VPA 19
VPA + LTG 1
VPA + LTG + PB 1
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one of JME patients with IGS changed into normal after TMS
examinations. Other patients’ EEGs were the same before and after
TMS. There were no signiﬁcant differences between the ﬁrst and
second EEG recordings (K = 0.84) No seizures were recorded during
or after the TMS study.
ANOVA analysis revealed signiﬁcant differences of RMT values,
CMCT and CSP durations between the three groups (F = 50.3;
p < 0.001; F = 4.26; p = 0.019; F = 3.39; p = 0.04; respectively) RMT
values of JME patientswere found to be higher than those of AS and
controls (p < 0.001, p < 0.001; respectively). On the other hand, we
did not ﬁnd any signiﬁcant differences between AS and controls
(p = 0.951). There were no differences between cortical MEP
amplitude and MEP/CMAP ratio in the three groups (F = 0.43
p = 0.652; F = 1.64 p = 0.203; respectively). CMCT duration was
shorter in JME patients than AS (p = 0.021). However, therewere no
signiﬁcant differences between normal controls and in both JME
patients and AS (p = 0.073, p = 0.727). CSP durationwas found to be
longer in JME patients as compared to the control group
(p = 0.037). In AS, CSP duration was also found to be longer than
controls but this difference was not considered to be statistically
signiﬁcant (p = 0.071) (Table 3).Table 2
EEG results of three study groups before and after TMS.
Before TMS After TMS
JME AS Controls JME AS Controls
SPSWP 6 1 () 5 1 ()
IGS 3 6 () 3 6 ()
Normal 12 14 20 13 14 20
SPSWP: spike/polyspike and wave paroxysms.
IGS: Intermittent generalized slowing.
Table 3
MEP results of juvenile myoclonic epileptic patients (JME), their asymptomatic
siblings (AS) and normal controls.
JME AS Controls F p
RMT (%) 46.8  4.0 34.4  4.8 34.8  4.8 50.3 <0.001
MEP amp (mV) 2.1  0.5 2.0  0.4 2.0  0.3 0.43 0.652
MEP/CMAP 0.198 0.182 0.189 1.64 0.203
CMCT (ms) 9.0  1.0 10.0  1.4 9.7  0.8 4.26 0.019
CSP (ms) 224.5  36.1 221.4  35.6 198.1  34.7 3.39 0.04
RMT: resting motor threshold.
MEP amp: cortical MEP amplitude.
MEP/CMAP: MEP amplitude/compound muscle action potential amplitude.
CMCT: central motor conduction time.
CSP: cortical silent period.4. Discussion
Our results showed that RMT was higher, CSP was longer and
CMCT was shorter in JME patients. In the literature, several TMS
studies yielded different results. Although in some of these studies
MT and CSP duration were not found to be different than normals;
in some of them higher or lower MT and longer or shorter CSP
duration were reported in epileptic patients compared to normals.
These differences have been proposed to be related to the type of
epilepsy, antiepileptic drug (AED) intake and also to methodology
(using circular vs 8 shaped coil, different stimulus intensity
etc.).2,5,27 Reutens et al. reported that MT was lower in untreated
patients with idiopathic generalized epilepsy (IGE) than normals,
but they found higher MT after starting anticonvulsant therapy.
They suggested that these results might indicate cortical hyper-
excitability in this group.2,5,11,27 In Macdonell et al.’s study, RMT
abnormalities were not shown in IGE patients, similarly, Tataroglu
et al. did not ﬁnd any differences in activated motor threshold
(AMT) of IGE patients compared to controls.16,20 Delvaux et al.
documented that both RMT and AMT were higher in untreated
patients who experienced ﬁrst generalized tonic clonic seizure
(GTCS) in the previous 48 h than normals and after 2–4 weeks MT
was not found different from normals. They proposed that these
results could indicate protectivemechanisms against the spread or
recurrence of seizure.15 In untreated focal epileptic patients, RMT
was not signiﬁcantly different from normals in two studies, but in
another study MT was found lower than normals.26,28,30 However,
in treated focal epileptic patients, RMT and/or AMT was higher
than normal controls.8,20,29 Manganotti et al. did not observe any
signiﬁcant differences in both RMT and AMT, MEP amplitude and
intracortical facilitation between JME patients and controls. But in
these studies, three JME patients did not take any antiepileptic
drugs and at the same time the dosage of AEDwas also low inmost
of JME patients.41,42 In our study, all JME patients were using AED
in therapeutic levels andwe also found that RMTwas higher in JME
patients than their AS and controls.
In our present study, we found longer CSP duration in JME
patients than controls. The studies in ‘‘treated’’ patients with
partial epilepsy had contradictory results. In two different studies
by Cantello et al. and Tataroglu et al., CSP was not found to be
different from normals.13,20 Cincotta et al. reported prolongation of
CSP duration,34 in contrast, Hamer et al. found shorter CSP in the
epileptic hemisphere compared to the contralateral hemisphere
and they suggested these ﬁndings might be related to synaptic
reorganization.29 In two other studies (Werhahn et al.; Varrasi
et al.), in ‘‘untreated’’ patients with partial epilepsy, CSP duration
was not different from normals.26,28 Macdonell et al. reported that
CSP duration increased in ‘‘untreated’’ IGE patients compared to
normals.16 But Tataroglu et al. found prolongation of CSP duration
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Moreover, in a group of ‘‘untreated’’ patients who were tested
after their ﬁrst GTCS,
CSP was not different from normals.15 In a heterogeneous series
of patients with generalized and partial seizure, prolongation of
CSP was found most prominent in epileptic patients with
uncontrolled seizures under medication.14 Manganotti et al. did
not observe any signiﬁcant differences of CSP durations between
JME patients and controls but found less MEP inhibition with 1 to
4 ms interstimulus intervals using paired pulse TMS (ppTMS).41
Our results showed CSP prolongation in JME patients and their AS
by contrast with Manganotti et al.’s study.
In the literature, except one study, CMCT changes in epileptic
patients were not reported. Hufnagel et al. asserted higher MT
intensities and prolonged peripheral latencies in medically
intractable epileptic patients. They found lower MTs and shorter
peripheral latencies after decreasing antiepileptic therapy. They
also noticed that CMCT was signiﬁcantly decreased in patients
with high frequency of seizures and after reducing antiepileptic
drugs. They proposed that central motor pathways were endo-
genously facilitated by epileptiform activity.8 In consistence with
this study, we also found shorter CMCT in JME patients than their
AS. But there were no signiﬁcant differences between JME patients
and normals. We considered that these results should be
interpreted with care and re-evaluated in further studies.
Transcranial magnetic stimulation provided not only evalua-
tion of motor cortical excitability but also the pharmacological
effects of antiepileptic therapy. Most of the studies showed that
antiepileptic drugs (AEDs) which act by voltage-gated sodium
channels such as phenytoin (PHT), carbamezepine (CBZ), valproate
(VPA) and lamotrigine (LTG) increasedMT in epileptic patients and
in normal subjects after loading dose.2,5,12,18,21,27 In contrast, AEDs
or other drugs enhancing GABA mediated inhibitory neurotrans-
mission, such as lorazepam (LZP), diazepam (DZP), vigabatrin
(VGB), gabapentin (GBP), baclofen (BAC) had no effect on
MT.2,5,12,27,36 On the other hand, PHT and LTG had no effect on
CSP, whereas CBZ, LZP, GBP, BAC increased CSP duration and DZP
produced a dose-dependent decreasing of CSP duration.2,5,27 Our
results showed higher MT and prolonged CSP in JME patients than
controls. These ﬁndings might be attributed to drug effect. All of
our patients were treated by VPA, one of themwas also taking LTG
and another patient was also using LTG and PB. Although VPA and
LTG inhibit voltage-gated sodium channels; VPA also enhances
GABA-mediated inhibitory neurotransmission.2,5,22,27 Reutens
et al. reported that untreated IGE patients had lower MT than
controls, however, after VPA therapy, MT signiﬁcantly increased in
IGE patients. They proposed that cortical excitability increased in
IGE patients and reduced by following AED treatment.2,11 In
contrast, Ziemann et al. observed that VPA had no effect onMT and
CSP; LTG increased MT and did not change CSP duration. They
suggested that this might be related to a low loading dose or
delayed antiepileptic effect of VPA.2 In our study, increased RMT
may be referred to VPA effects. As reported by Ziemann et al., both
VPA and LTG had no effect on CSP duration and prolongation of CSP
in JME patients might reﬂect impairment of supraspinal and/or
intracortical inhibitory mechanism instead of drug effect.
Although there are concerns about the fact that TMS may
induce seizures or kindling a seizure focus, some former studies
showed that single-pulse TMS stimulation was safe in normal
subjects and even in epileptic patients.1–3,6,10,13,20,27,44,45,47 In
some early studies, authors observed focal seizures triggered by
TMS in epileptic patients.44,46 Hufnagel et al. found the probability
of inducing seizure with spTMS to be lower than 5% in epileptic
patients and this probability increased with low serum anti-
epileptic drug level, recently experienced spontaneous seizure,
continuous epileptic activity on EEG before TMS and application ofTMS on epileptic focus.1,47 Cantello et al. also declared that single
and paired TMS did not cause seizure or EEG changes in
cryptogenic localization-related epileptic patients.13 Tataroglu
et al. reported no clinical seizures just after TMS in their epileptic
patients. They observed those patients for four weeks and did not
ﬁnd any signiﬁcant differences between seizure frequency before
and after TMS.20 Schrader et al. reviewed published data and tried
to determine seizure risk associatedwith single- and paired TMS in
epileptic patients. They observed that medically intractable
patients and low AED serum level increased the probability of
inducing a seizure.47 In our study, although six of JME patients and
one asymptomatic sibling had 4–6 Hz spike/polyspike and wave
paroxysms on EEG examination before TMS; we also did not notice
any seizures in our study groups. After TMS examinations, one of
our JME patients who had paroxysms on ﬁrst EEG examination,
paroxysms changed into IGS and another JME patient who had IGS
before TMS, EEG examination was found to be normal. Our results
are consistent with the literature ﬁndings which report TMS as a
safe electrophysiological tool for investigating of motor cortex
excitability in epileptic patients.
In conclusion, our results showed that RMT was higher in JME
patients and CSP was longer in JME patients and their AS. Although
high MT might be due to drug effect, the prolongation of CSP
duration might reﬂect impairment of supraspinal and/or intra-
cortical inhibitorymechanism. To eliminate the drug effect, further
studies are needed in newly diagnosed JME patients without
medication and large series of their asymptomatic siblings.
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